Created at	Source	Raw Value	Validated value
Dec. 9, 2021, 12:30 a.m.	usa	Evaluation of SARS-CoV2 Neutralizing Antibodies;Protection rates of Turkovac and CoronaVac vaccines against symptomatic COVID-19;T-Cell Evaluation;To Evaluate the SARS-CoV2 anti-spike protein immunoglobulin G	Evaluation of SARS-CoV2 Neutralizing Antibodies;Protection rates of Turkovac and CoronaVac vaccines against symptomatic COVID-19;T-Cell Evaluation;To Evaluate the SARS-CoV2 anti-spike protein immunoglobulin G
Oct. 29, 2021, 11:30 a.m.	usa	Protection rates of Turkovac and CoronaVac vaccines against symptomatic COVID-19	Protection rates of Turkovac and CoronaVac vaccines against symptomatic COVID-19
Oct. 16, 2021, 3 p.m.	usa	To evaluate the efficacy of booster doses of inactivated COVID-19 vaccines	To evaluate the efficacy of booster doses of inactivated COVID-19 vaccines